News

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative…

1 year ago

Assure Holdings Reports Second Quarter 2023 Financial Results

DENVER, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative…

1 year ago

Nextech Launches New Med Spa Software that Drives Facility Growth in a Rapidly Evolving Industry

TAMPA, Fla., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Nextech, a complete healthcare technology solution for specialty providers, announced today the…

1 year ago

CYCLE Kids Launches Brooklyn-Based Fundraising Campaign

Non-profit to Kick Off Back-to-School Campaign with a Times Square Billboard on National Non-Profit Day CYCLE Kids A Bike Can…

1 year ago

Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program

-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned…

1 year ago

Akari Therapeutics, Plc Announces ADS Ratio Change

NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

1 year ago

Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards

RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading…

1 year ago

Carhartt Inc. and CorVel Corporation Named Risk Management Team of the Year in 2023 U.S. Insurance Awards

FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Carhartt Inc., one of America’s leading manufacturers of durable workwear and…

1 year ago

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients…

1 year ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:…

1 year ago